CSBio CSBio

X
[{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Richter and Hikma Sign Exclusive Commercialisation and License Agreement for Denosumab in the US, a Proposed Biosimilar Referencing Prolia\u00ae and Xgeva\u00ae","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"HUNGARY","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Gedeon Richter"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            According to the agreement, Richter is responsible for the development of the denosumab, Products (to conduct both Phase 1 and Phase 3 global clinical studies) and will supply finished commercial Products for the US market.

            Lead Product(s): Denosumab

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Hikma Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement December 09, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY